The Mevalonate hypothesis: A cholesterol-independent alternative for the etiology of atherosclerosis

Lipids in Health and Disease

Volumn 11, Issue , 2012, Pages

  Keizer, Hiskias G ^a  

^a Stepan Specialty Products BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FREE RADICAL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TORCETRAPIB;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; ENZYME ACTIVATION; FAMILIAL HYPERCHOLESTEROLEMIA; FOAM CELL; META ANALYSIS (TOPIC);

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL; FREE RADICALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; METABOLIC NETWORKS AND PATHWAYS; MEVALONIC ACID; MODELS, CARDIOVASCULAR;

NEGIBACTERIA;

EID: 84868235786     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-11-149     Document Type: Article

References (58)

1. An interpretive history of the cholesterol controversy: Part I. Steinberg D, J Lipid Res 2004 45 1583 1593 10.1194/jlr.R400003-JLR200 15102877 (Pubitemid 39296197)
2. An interpretive history of the cholesterol controversy: Part II: the early evidence linking hypercholesterolemia to coronary disease in humans. Steinberg D, J Lipid Res 2005 46 179 190 15547293 (Pubitemid 40271080)
3. An interpretive history of the cholesterol controversy: Part III: mechanistically defining the role of hyperlipidemia. Steinberg D, J Lipid Res 2005 46 2037 2051 10.1194/jlr.R500010-JLR200 15995167 (Pubitemid 41377456)
4. An interpretive history of the cholesterol controversy: Part IV:The 1984 coronary primary prevention trial ends it-almost. Steinberg D, J Lipid Res 2006 47 1 14 16227628 (Pubitemid 43107444)
5. An interpretive history of the cholesterol controversy: PartV: The discovery of the statins and the end of the controversy. Steinberg D6, J Lipid Res 2006 47 1339 1351 10.1194/jlr.R600009-JLR200 16585781 (Pubitemid 44079887)
6. Effect of a high intake of conjugated-linoleic acid on lipoprotein levels in healthy humans subjects. Wanders AJ, Brouwer IA, Siebelink E, Katan MB, PLoS One 2010 5 2 9000 10.1371/journal.pone.0009000 20140250
7. Uber den gehalt nirmaler und atheromatoser aorten on cholsterin und cholesterinestern. Hoppe-Seylers. Windaus A, Z Physiol Chem 1910 67 174 176 10.1515/bchm2.1910.67.2.174
8. Ueber experimentelle Choleserinsteatose und ihre Bedeutung fur die Entstehung einiger pathologischer Prozesse. Anitschkow NN, Zentralbl Allg Pathol 1913 24 1 9
9. Angina pectoris in heriditary xanthomatosis. Muller L, Arch Intern Med 1939 64 675 700 10.1001/archinte.1939.00190040016002
10. The role of lipids and lipoproteins in atherosclerosis. Gofman JW, Lindgren F, Elliott H, Mantz W, Hewitt J, Herring V, Science 1950 111 166 171 10.1126/science.111.2877.166 15403115
11. Protein-lipid relationships in human plasma. II. In atherosclerosis and related conditions. Barr DP, Russ EM, Adler HE, Am J Med 1951 11 480 488 10.1016/0002-9343(51)90183-0 14885223
12. Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3- methylglutaryl coenzyme A reductase activity. Brown MS, Goldstein JL, Proc Natl Acad Sci USA 1974 71 788 792 10.1073/pnas.71.3.788 4362634
13. Cholesterol transport between cells and body fluids. Role of plasma lipoproteins and the plasma cholesterol esterification system. Fielding CJ, Fielding PE, Med Clin North Am 1982 66 363 373 7040842 (Pubitemid 12115371)
14. Factors of risk in the development of coronary heart diseasesix year follow-up experience. The Framingham Study. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J, Ann Intern Med 1961 55 33 50 13751193
15. Dietary modification of serum cholesterol and phospholipid levels. Kinsell LW, Partridge J, Boling L, Margen S, Michael G, J Clin Endocrinol Metab 1952 12 909 913 14938428
16. The effect of plasma cholesterol lowering diet in male survivors of myocardial infarction. A controlled clinical trial. Leren P, Acta Med Scand 1966 466 Suppl 1 92
17. Keys, Seven Countries: A Multivariate Analysis of Death and Coronary Heart Disease Cambridge: Harvard University Press 1980 ISBN 0-674-80237-3
18. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. Lipid Research Clinics Coronary Primary Prevention Trial, J Am Med Assoc 1984 251 365 374
19. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Scandinavian Simvastatin Survival Study Group, Lancet 1994 344 1383 1389 7968073
20. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl EA, Wu P, Blechacz B, Bassler D, Wei X, Sharman A, Whitt I, Alves Da Silva S, Khalid Z, Nordmann A, Zhou Q, Walter SD, Vale N, Bhatnagar N, ORegan C, Mills EJ, Bucher HC, Montori VM, Guyatt GH, BMJ 2009 338 92 10.1136/bmj.b92 19221140
21. LCAT, HDL Cholesterol and Ischemic Cardiovascular Disease: A Mendelian Randomization Study of HDL Cholesterol in 54,500 Individuals. Haase L, Tybjærg-Hansen A, Ali Qayyum A, Schou J, Nordestgaard BG, Frikke-Schmidt R, J Clin Endocrinol Metab 2012 97 2 248 E256 10.1210/jc.2011-1846 22090275
22. Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E, JAMA 1998 280 605 13 10.1001/jama.280.7.605 9718051 (Pubitemid 28502636)
23. For the RADIANCE 1 Investigators: Effect of Torcetrapib on Carotid Atherosclerosis. Kastelein JJP, Van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML, N Engl J Med 2007 356 1620 1630 10.1056/NEJMoa071359 17387131 (Pubitemid 46631671)
24. for the ENHANCE Investigators: Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. Kastelein JJP, Akdim F, Stroes ESG, Zwinderman AH, Bots ML, Stalenhoef AFH, Frank FCRP, Visseren LJ, Sijbrands EJG, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, De Groot E, N Engl J Med 2008 358 1431 1443 10.1056/NEJMoa0800742 18376000 (Pubitemid 351482735)
25. For the AURORA Study Group: Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. Beng C, Fellström MD, Jardine AG, Roland E, Schmieder MD, Hallvard Holdaas MD, et al. N Engl J Med 2009 360 1395 1407 10.1056/NEJMoa0810177 19332456
26. Efficacy and safety of atorvastatin in the prevention of cardiovascular endpoints in subjects with type 2 diabetes. The Atorvastatin study for prevention of coronary heart disease endpoints in non-insulin dependent diabetes mellitus (ASPEN). Knopp RH, dEmden M, Smilde JG, Pocock SJ on behalf of the ASPEN study group, Diabetes Care 2006 29 7 1478 1485 10.2337/dc05-2415 16801565 (Pubitemid 44127567)
27. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. Wanner C, Krane V, Marz W, Olschewski M, Mann JFE, Ruf G, Ritz E, N Engl J Med 2005 353 238 248 10.1056/NEJMoa043545 16034009 (Pubitemid 41058323)
28. The Gissi-HF investigators: Effect of Rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Tavazzi L, Maggioni AP, Marchioli R, et al. Lancet 2008 372 1231 12 10.1016/S0140-6736(08)61240-4 18757089
29. The clinical use of HMGCoA reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications. Langsjoen PH, Langsjoen AM, Biofactors 2003 18 101 111 10.1002/biof.5520180212 14695925 (Pubitemid 38030704)
30. Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. Mohr D, Bowry V, Stocker R, Biochim Biophys Acta 1992 1126 247 254 10.1016/0005-2760(92)90237- P 1637852
31. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Folkers K, Vadhanavikit S, Mortensen SA, PNAS 1985 82 901 904 10.1073/pnas.82.3.901 3856239 (Pubitemid 15142785)
32. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Miettinen T, Gylling H, BMJ 1998 316 1127 10.1136/bmj.316.7138.1127 9552949
33. Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients. Relation to basal serum cholestanol. Miettinen TA, Strandberg TE, Gylling H, for the Finnish Investigators of the Scandinavian Simvastatin Survival Study Group, Arterioscler Thromb Vasc Biol 2000 20 1340 1346 10.1161/01.ATV.20.5.1340 10807752 (Pubitemid 30262937)
34. Role of oxidative modifications in atherosclerosis. Stocker R, Keaney JF, Physol Rev 2004 84 4 1381 1478 10.1152/physrev.00047.2003 (Pubitemid 39302636)
35. Rac regulates cardiovascular superoxide through diverse molecular interactions: more than a binary GTP switch. Gregg D, Rauscher FM, Goldschmidt-Clermont PJ, Am J Physiol Cell Physiol 2003 285 4 723 C734 12958025
36. NADPH Oxidase in Endothelial Cells: Impact on Atherosclerosis. Rueckschloss U, Antioxid Redox Signal 2004 5 2 171 180
37. Association between the C242T polymorphism in the p22phox gene with arterial stiffness in the Brazilian population. de Oliveira Alvim R, Lima Santos PC Jr, Gonçalves Dias R, Velho Rodrigues M, de Sa Cunha R, Mill JG, Nadruz W Jr, Krieger JE, Costa Pereira A, Physiol Genomics 2012 44 10 587 592 10.1152/physiolgenomics.00122.2011 22496489
38. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. Brown MS, Goldstein JL, J Lipid Res 1980 21 505 517 6995544 (Pubitemid 11194847)
39. Withdrawel of 3-hydroxy-3-methylglutaryl Coenzyme A reductase inhibitors elicit oxidative stress and induces endothelial dysfunction in mice. Vecchione C, Brandes RP, Circulation res 2002 91 173 179 10.1161/01.RES.0000028004.76218. B8 12142351 (Pubitemid 34827229)
40. Cholesterol synthesis inhibition elicits an integrated molecular response in human livers including decreased ACAT2. Parini P, Gustafsson U, Davis MA, Larsson L, Einarsson C, Wilson M, Rudling M, Tomoda H, Omura S, et al. Arterioscler Thromb Vasc Biol 2008 28 1200 1206 10.1161/ATVBAHA.107.157172 18340009
41. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. Reihner E, Rudling M, Stahlberg D, Berglund L, Ewerth S, Bjorkhem I, Einarsson K, Angelin B, N Engl J Med 1990 323 224 8 10.1056/NEJM199007263230403 2114543 (Pubitemid 20225042)
42. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Blanco M, Nombela F, Castellanos M, Rodriguez-Yanez M, Garcia-Gil M, Leira R, Lizasoain I, Serena J, Vivancos J, et al. Neurology 2007 69 904 10 10.1212/01.wnl.0000269789.09277.47 17724294 (Pubitemid 47329591)
43. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Heeschen C, Hamm CW, Laufs U, Snapinn S, Bohm M, White HD, Circulation 2002 105 1446 1452 10.1161/01.CIR.0000012530.68333.C8 11914253 (Pubitemid 34263276)
44. Rebound inflammatory response during the acute phase of myocardial infarction after simvastatin withdrawal. Sposito AC, Carvalho LS, Cintra RM, Araujo AL, Ono AH, Andrade JM, Coelho OR, Silva JC Qe, Atherosclerosis 2009 207 191 194 10.1016/j.atherosclerosis.2009.04.008 19464010
45. Short-term withdrawal of simvastatin induces endothelial dysfunction in patients with coronary artery disease: a dose-response effect dependent on endothelial nitric oxide synthase. Chen H, Ren JY, Xing Y, Zhang WL, Liu X, Wu P, Wang RJ, Luo Y, Int J Cardiol 2009 131 313 320 10.1016/j.ijcard.2007.10.044 18221806
46. Familial Hypercholesterolemia: Identification of a Defect in the Regulation of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Activity Associated with Overproduction of Cholesterol. Goldstein JL, Brown MS, PNAS 1973 70 10 2804 2808 10.1073/pnas.70.10.2804 4355366
47. Oxidative Stress Is Associated With Arterial Dysfunction and Enhanced Intima-Media Thickness in Children With Hypercholesterolemia: The Potential Role of Nicotinamide-Adenine Dinucleotide Phosphate Oxidase. Martino F, Loffredo L, Carnevali R, Sanguigni V, Martino E, Catasca E, Zanoni C, Pignatelli P, Violi F, Pediatrics 2008 122 3 648 e655 10.1542/peds.2008-0735 18762499
48. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Song Y, Stampfer MJ, Liu S, Ann Intern Med 2004 141 2 137 47 15262670 (Pubitemid 38937836)
49. Trans fatty acids and cardiovascular disease. Mozaffarian D, Katan MB, Ascherio A, Stampfer MJ, Willett WC, N Engl J Med 2006 354 1601 1613 10.1056/NEJMra054035 16611951
50. Trans-fatty acids induce a proinflammatory response in endothelial cells through ROS-dependent nuclear factor Kappa B activation. Bryk D, Zapolska-Downar D, Melecki M, Hajdukiewicz D, Sitkiewicz D, J Phys Pharmacol 2011 62 2 229 238
51. Exchanging partially hydrogenated fat for palmitic acid in the diet increases LDL-cholesterol and endogenous cholesterol synthesis in normocholesterolemic women. Sundram K, French MA, Clandinin MT, Eur J Nutr 2003 42 188 94 10.1007/s00394-003-0411-9 12923649 (Pubitemid 36999070)
52. Low level endotoxin induces potent inflammatory activation of human blood vessels. Rice JB, Stoll LL, Li W-G, Denning GM, Weydert J, Charipar E, Richenbacher WE, Miller FJ Jr, Weintraub NL, Arterioscl Throm Vasc Biol 2003 23 1576 1582 10.1161/01.ATV.0000081741.38087.F9 (Pubitemid 37108200)
53. High cholesterol may protect against infections and atherosclerosis. Ravnskov U, Q J Med 2003 96 927 934 10.1093/qjmed/hcg150 (Pubitemid 37540668)
54. Human endothelial cells are activated by interferon- plus tumour necrosis factor- to kill intracellular Pseudomonas aeruginosa. De Assis MC, Da Costa AO, Barja-Fidalgo TC, Plotkowsk MC, Immunology 2000 101 2 271 278 10.1046/j.1365-2567.2000.00102.x 11012781
55. Serum total cholesterol and risk of hospitalization and death from respiratory disease. Iribarren C, Jacobs DR Jr, Sidney S, Claxton AJ, Gross MD, Sadler M, Blackburn H, Int J Epidemiol 1997 26 1191 1202 10.1093/ije/26.6.1191 9447398 (Pubitemid 28010436)
56. Cohort study of serum total cholesterol and in-hospital incidence of infectious diseases. Iribarren C, Jacobs DR Jr, Sidney S, Claxton AJ, Feingold KR, Epidemiol Infect 1998 121 335 347 10.1017/S0950268898001435 9825784 (Pubitemid 28493152)
57. Role of circulating lipoproteins in protection from endotoxin toxicity. Feingold KR, Funk JL, Moser AH, Shigenaga JK, Rapp JH, Grunfeld C, Infect Immun 1995 63 2041 2046 7729918
58. Homocysteine Induces 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase in Vascular Endothelial Cells. A Mechanism for Development of Atherosclerosis? Li H, Lewis A, Brodsky S, Rieger R, Iden C, Goligorsky MS, Circ 2002 105 1037 1043 10.1161/hc0902.104713 (Pubitemid 34212610)